文献速递生殖医学

ICSI后完全受精失败:通过人工卵母细胞激活对病理生理、诊断和管理的深入见解

Total fertilization failure after ICSI: insights into pathophysiology, diagnosis, and management through artificial oocyte activation.
PubMed 文献 · Hum Reprod Update · 2023-01-01

该综述总结ICSI后完全受精失败(TFF)的病理生理、诊断及人工卵母细胞激活(AOA)治疗。TFF影响1-3%的ICSI周期,卵母细胞激活缺陷(OAD)是主因,涉及精子或卵母细胞因素。AOA对精子PLCζ缺陷所致TFF高效,但对卵母细胞因素者需替代激活剂;AOA可能引起胚胎表观遗传改变,应谨慎使用。

要点

  • TFF影响1-3%的ICSI周期,OAD是主要原因
  • 常规AOA对PLCζ精子缺陷所致TFF高效
  • 卵母细胞因素所致TFF可用替代AOA激活剂

核心结论

  • AOA是克服精子和卵母细胞相关因素所致受精失败的有前景疗法。
  • 诊断受精失败原因对提高AOA疗效和安全性至关重要。
  • 多数数据未显示AOA对胚胎发育的不良影响,但文献稀缺,近期小鼠研究提示AOA可能引起胚胎和子代表观遗传改变。
  • 在更可靠数据可用前,AOA应临床审慎应用,且仅在适当患者咨询后使用;目前应视为创新性治疗而非成熟疗法。

研究设计与样本

  • 综述,检索PubMed英文文献,纳入截至2022年11月的相关研究。
  • 检索词包括受精失败、AOA、PLCζ、PLCZ1突变、卵母细胞相关因素、WEE2突变、PATL2突变、TUBB8突变和TLE6突变。

主要发现

  • TFF影响1-3%的ICSI周期,OAD是受精失败的主要原因,归因于精子或卵母细胞相关问题。
  • 受精失败主要与精子PLCζ缺陷相关,缺陷PLCζ无法触发细胞内Ca2+振荡。
  • 卵母细胞缺陷中已识别WEE2、PATL2、TUBB8和TLE6等基因突变,导致Ca2+信号转导缺陷和MPF灭活受阻。
  • 常规AOA策略基于诱导钙振荡,对PLCζ精子缺陷所致受精失败高效;卵母细胞相关缺陷可能通过替代AOA激活剂如cycloheximide、TPEN、roscovitine和WEE2互补RNA管理。
  • 卵母细胞不成熟所致OAD,应用改良卵巢刺激方案和触发可改善受精。

关键数值与推荐

  • TFF影响1-3%的ICSI周期。
  • 诊断测试包括异源和同源测试、粒子图像测速、免疫染色和基因检测。
  • 替代AOA激活剂包括cycloheximide、N,N,N',N'-四(2-吡啶甲基)乙二胺(TPEN)、roscovitine和WEE2互补RNA。

临床怎么用

  • AOA应临床审慎应用,且仅在适当患者咨询后使用。
  • 目前AOA应视为创新性治疗,而非成熟疗法。
  • 诊断受精失败原因对提高AOA疗效和安全性至关重要。

局限性

  • 数据稀缺且接受AOA的人群异质,难以对AOA疗效和安全性得出确切结论。
  • 文献稀缺,近期研究主要使用小鼠,提示AOA可能引起胚胎和子代表观遗传改变。
  • 在更可靠数据可用前,AOA应审慎应用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Total fertilization failure (TFF) is the failure of all metaphase II oocytes to fertilize in ART cycles. The phenomenon represents a known cause of infertility, affecting 1-3% of ICSI cycles. Oocyte activation deficiency (OAD) is the leading cause of fertilization failure, attributed to sperm- or oocyte-related issues, although until recently little attention has been given to oocyte-related deficiencies. Different strategies for overcoming TFF have been proposed in clinical settings, mainly using artificial oocyte activation (AOA) by calcium ionophores. Typically, AOA has been blindly applied with no previous diagnosis testing and, therefore, not considering the origin of the deficiency. The scarcity of data available and the heterogeneous population subjected to AOA make it challenging to draw firm conclusions about the efficacy and safety of AOA treatments. OBJECTIVE AND RATIONALE: TFF leads to an unexpected, premature termination of ART, which inflicts a substantial psychological and financial burden on patients. This review aims to provide a substantial update on: the pathophysiology of fertilization failure, focusing both on sperm- and oocyte-related factors; the relevance of diagnostic testing to determine the cause of OAD; and the effectiveness and safety of AOA treatments to overcome fertilization failure. SEARCH METHODS: Relevant studies were identified in the English-language literature using PubMed search terms, including fertilization failure, AOA, phospholipase C zeta (PLCζ), PLCZ1 mutations, oocyte-related factors, wee1-like protein kinase 2 (WEE2) mutations, PAT1 homolog 2 (PATL2) mutations, tubulin beta-8 chain (TUBB8) mutations, and transducin-like enhancer protein 6 (TLE6) mutations. All relevant publications until November 2022 were critically evaluated and discussed. OUTCOMES: Fertilization failure after ART has been predominantly associated with PLCζ deficiencies in sperm. The reason relates to the well-established inability of defective PLCζ to trigger the characteristic pattern of intracellular Ca2+ oscillations responsible for activating specific molecular pathways in the oocyte that lead to meiosis resumption and completion. However, oocyte deficiencies have recently emerged to play critical roles in fertilization failure. Specifically, mutations have been identified in genes such as WEE2, PATL2, TUBB8, and TLE6. Such mutations translate into altered protein synthesis that results in defective transduction of the physiological Ca2+ signal needed for maturation-promoting factor (MPF) inactivation, which is indispensable for oocyte activation. The effectiveness of AOA treatments is closely related to identifying the causal factor of fertilization failure. Various diagnostic tests have been developed to determine the cause of OAD, including heterologous and homologous tests, particle image velocimetry, immunostaining, and genetic tests. On this basis, it has been shown that conventional AOA strategies, based on inducing the calcium oscillations, are highly effective in overcoming fertilization failure caused by PLCζ-sperm deficiencies. In contrast, oocyte-related deficiencies might be successfully managed using alternative AOA promoters that induce MPF inactivation and meiosis resumption. Such agents include cycloheximide, N,N,N',N'-tetrakis(2-pyridylmethyl)ethane-1,2-diamine (TPEN), roscovitine, and WEE2 complementary RNA. In addition, when OAD is caused by oocyte dysmaturity, applying a modified ovarian stimulation protocol and trigger could improve fertilization. WIDER IMPLICATIONS: AOA treatments represent a promising therapy to overcome fertilization failure caused by sperm- and oocyte-related factors. Diagnosing the cause of fertilization failure will be essential to improve the effectiveness and safe utilization of AOA treatments. Even though most data have not shown adverse effects of AOA on pre- and post-implantation embryo development, the literature is scarce on the matter concerned and recent studies, mainly using mice, suggest that AOA might cause epigenetic alterations in the resulting embryos and offspring. Until more robust data are available, and despite the encouraging results obtained, AOA should be applied clinically judiciously and only after appropriate patient counseling. Currently, AOA should be considered an innovative treatment, not an established one.

来源:Hum Reprod Update,查看原文。版权归原作者所有。

引用

  1. Campos G, Sciorio R, Esteves SC, et al. Total fertilization failure after ICSI: insights into pathophysiology, diagnosis, and management through artificial oocyte activation. Hum Reprod Update. 2023. PMID: 36977357. doi:10.1093/humupd/dmad007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。